B2M and melanoma: Zaretsky et al. also found that melanoma patients who relapsed after 14.9 months of Pembrolizumab treatment had a 4-base deletion frameshift mutation in exon 1 of the β2M gene, which abolished MHC-I membrane localization, thus causing immune therapy resistance[74].